



Marijke De Saint-Hubert - 4/2/2021

Radiotherapy during pregnancy



- 1. Current clinical practice & data
- 2. Dosimetry in pregnancy radiotherapy
- 3. Potential benefit from advanced radiotherapy
 - 4. EURADOS activities & plans



Reference

Current clinical practice

- 1 in 1000 pregnancies are complicated with cancer
- More than 70% of patients are treated during pregnancy
- Radiotherapy is only applied in <u>3% of the cases</u>
 - Mostly breast (54%) and brain cancers (15%)
 - In first trimester can be an alternative to chemotherapy avoiding treatment delays
 - Generally radiotherapy is postponed till after delivery
- Radiotherapy during pregnancy treated as a prohibited topic
 - → Lack of reliable information on the <u>risk</u> of fetal damage
 - → Lack of data on the <u>dose</u> to the fetus during pregnancy
 - → What dose is considered <u>allowed</u>?
 - → ICRP Threshold for deterministic effects (e.g. malformations) 100-200 mGy
 - → Generally a threshold of 100 mGy is used
 - → No threshold for risk of cancer

| Stage of pregnancy | Therapeutic options |
|--------------------|---------------------|
| First trimester | Surgery |
| | Radiotherapy |
| Second trimester | Surgery |
| | Radiotherapy |
| | Chemotherapy |
| Third trimester | Surgery |
| | Chemotherapy |


F. Amant, et al., European Journal of Cancer 2010

General aspects of RT during pregnancy

- Fetus dose is dependent on cancer position
 - Larger the distance between tumor and fetus the better
 - Generally assumed for upper body parts RT is possible
- Fetus dose will also depend on the stage of pregnancy
 - 1st trimester is further than 2nd and 3rd trimester
 - Safe RT < 3rd trimester
- Fetal shielding is generally applied in conventional radiotherapy
 - Dose reduction factor 2-4
 - Heavy materials
 - Strong supports
 - Risks
 - Lead apron
 - Not very comfortable for patient



F. Amant et al. / Best Practice & Research Clinical Obstetrics and Gynaecology 29 (2015)





T Vandenbroucke, et al. The Lancet 2017. Effects of cancer treatment during pregnancy on fetal and child development



https://www.iaea.org/resources/rpop/health-professionals/radiology/pregnant-women

Imaging in radiotherapy process





Highly conformal treatments are routine – target positioning is critical -> imaging at each fraction
Image-Guided RadioTherapy



Clinical fetus dose data

Few studies on reported fetus doses and outcome

- Review paper HB Kal et al., reporting fetus dose during pregnancy photon radiotherapy
 - Breast carcinoma: fetus dose 40-180 mGy
 - Hodgkin's disease: fetus dose 9-500 mGy
 - Brain tumours: fetus dose 3-90 mGy
- For breast and Hodgkin's disease shielding was always applied while for brain, H&N only in 1 case
- Outcomes of children are reassuring, but long-term followup is limited

| Maternal dose (Gy) | Fetal dose (Gy) | Pregnancy trimester | n | Delivery | Ref |
|---|--|---------------------|----|---|-----|
| Breast carcinoma* | | | | | |
| 50 | 0-160 | 3 | 1 | Healthy boy | 27 |
| 50 | 0.14-0.18 | 3 | 1 | | 28 |
| 46 | 0.039 | 1 | 1 | Healthy boy | 29 |
| Hodgkin's disease* | | | | | |
| 35-40 | 0-014-0-055 (6 MV) 0-100-0-136 (cobalt) | 1-3 | 16 | Healthy babies/ no malignant disease | 25 |
| 19 | 0-09-0-42, head 0-114 | 3 | 1 | Healthy child at age 8 years | 33 |
| 15-20 | 0.020-0.50 | 2-3 | 7 | Healthy children at age 6-11 years | 34 |
| | | | 16 | Healthy babies | 36 |
| 35 | <0.1 | 2 | 1 | Healthy child | 37 |
| Brain tumours, head and neck cancer† | | | | | |
| 64 | 0-027-0-086 | 2 | 1 | Healthy baby | 33 |
| 45 | 0.020 | 1 | 1 | | 41 |
| 25 | 0.0015-0.0031 | 3 | 1 | | 42 |
| 30 | 0.003 | 2 | 1 | Healthy boy at age 3 years | 43 |
| 68 | 0.06 | 3 | 1 | Healthy girl at age 2-5 years | 44 |
| 78-2 | 0.030 | 3 | 1 | Healthy girl at age 1.5 years | 44 |
| 66 | 0-033-0-086* | 3 | 1 | | 45 |
| With shielding. †Witho | ut shielding. | | | | |

H.B. Kal and H. Struikmans, Radiotherapy during pregnancy: fact and fiction, The Lancet Oncology 6(5), 328–333 (2005).

AAPM guidelines require the estimation and reduction of fetus dose

→ In clinical setting it is important to perform experiments in phantoms and/or Monte Carlo simulations to estimate fetus dose



Reference


Out-of-field doses during photon radiotherapy ------

Source of out-of-field doses


- (1) photon leakage through the treatment head of the machine
- (2) radiation scattered from the collimators
- (3) radiation scattered within the patient from the treatment beams

Out-of-field dose depends on

- → Treatment device (Siemens, Varian, Elekta)
- → Treatment technique
 - → Conformal, IMRT, VMAT, Cyberknife



Comparison of experimental WG9 EURADOS data to analytical model of different RT techniques and devices





Phantom measurements for out-of-field dosimetry

Water phantoms



Anthropomorphic






Pregnant women


- No commercial phantom exists
 - Water phantoms
 - No patient geometry and tissue composition
 - Rando phantom
 - 1st stage of pregnancy (uterus dose)
 - Rando plus PMMA/lucite slices
 - Belly of different sizes
 - Inserts for detectors
 - 3D printing technology
 - · Fetus organs can be modelled

Group from USA (Boston, MA) designed and built MRI phantom that mimics critical organs (torso, uterus, placenta, fetal brain and body) and typical fetal motion in pregnancy at 36-weeks of gestational age



LS Chitty 1994










Phantom measurements in clinics

Fetal dose measurements

- Anthropomorphic phantom is used
 - Slabs of phantom
 - Water phantom added




Z.E. Labby, et al. Rad Oncol Phys 2018



J.J. Nuyttens, et al. Cancer 2002

- Combination of phantom pieces and water bottles
- TLDs, Ionization chambers are inserted and/or place on phantom





Provided by A. Kuchcińska., et al. NIO-PIB, Warsaw Poland

Fetal dose optimization

- Beam parameters
- Positioning of patient
- Patient shielding
- Bladder filling

Computational fetal dosimetry

- Patient imaging data are limited to the treatment area
 - Fetus is not scanned to avoid imaging dose to the fetus
- Make use of computational phantoms
 - Katja phantom 24 weeks pregnancy (Helmholtz Zentrum Munich)
 - University of Florida family of anthropomorphic phantoms
 - 8, 10, 15, 25, 30 and 35w after conception

Figure 1. Katja and the foetus on the left hand side, on the right the primal model ICRP-AF. Clearly visible is the shifted colon. In the pelvis of ICRP-AF is the unchanged uterus J. Becker, et al. Pol J Med Phys Eng 2008






Figure 4. Models of the 9-month old fetus and the mother. (a) The adjusted skin surface model of the fetus model in mesh, (b) the adjusted skin model of the mother in mesh to accommodate for the fetus at 9-month gestation, (c) a surface rendering showing that the skin of the mother contains a 0-month old februs.



UF/NCI Phantom Library - Pregnant Females

The UF Family of hybrid phantoms of the pregnant female for computational radiation dosimetry Phys. Med. Biol. 59 (2014) 4325–4343 Matthew Riversed; Net is 3 Long. Rash 3 Meaward; Roser V Billini. Ann Miders: Carel Ford and



The UF family of hybrid phantoms of the developing human fetus for computational radiation dosimetry Phys. Med. Biol. 56 (2011) 4839-4879 Matthew R Maynard¹, John W Geyer¹, John P Arts², Roger Y Shiftin¹

In vivo patient dosimetry in clinics




Provided by A. Kuchcińska., et al. NIO-PIB

- Passive detectors on patient skin
- Assess skin dose and make use of phantom measurements for conversion to fetus dose



Sarcoma patient receiving RT during pregnancy





37y old pregnant women (21 weeks pregnant) with papilar meningioma (Grade III) is treated with 3D-CRT




1. Current clinical practice & data

2. Dosimetry in pregnancy radiotherapy

3. Potential benefit from advanced radiotherapy

4. EURADOS activities & plans








Proton therapy

- Protons slow down as beam enters the target area and releases is its energy at a tuneable depth in the tumour
 - Decreased entrance dose
 - No exit dose
- Few data exist on Proton Therapy during pregnancy
- Geng et al., 2015 calculated a 10-fold reduction in fetus dose during pregnancy
- Brain Pencil Beam Scanning versus 3D-CRT
 - PBS (1.5-2.5 uSv/Gy)
 - 3D-CRT (11-30uSv/Gy)

Pregnant fetus dose data during PT are limited







What are the dosimetry challenges?

- Protons interacting with beamline and patient creating secondary radiation
 - **Mixed field** radiation consisting of photons, protons, alphas and neutrons
 - Varying radiation qualities
 - Contribution to out-of-field dose depends on position out-of-field, patient orientation, beam parameters
 - Secondary neutrons
 - High-energy neutrons created by intra-nuclear cascades (up to maximum proton energy)
 - Fast neutrons evaporated by excited nuclei (few MeV)
 - Thermal neutrons by slowing down during collisions (0.25 eV)
- Neutron detectors for out-of-field dose assessment
 - Very specific detector material composition required
 - Thermal neutron detection based on $^6\text{Li}(n,\alpha)^3\text{H}$
 - Fast neutrons create recoil protons in Hydrogen rich materials → CR39 detectors
 - Need to be compact
 - Li6-enriched TLDs
 - CR39 detectors
 - Bubble detectors
 - Response is angular and energy dependent

Thermoluminescent detectors



Bubble detectors





Track etch detectors









What are the dosimetry challenges?

- Monte Carlo modeling of neutrons is challenging above 20 MeV
 - No cross section data exists and internuclear models are used
 - Strong dependency on the cross section libraries and models





M De Saint-Hubert, , M. Klodowska, M. T. Romero-Expósito, Jad Farah, K. Tyminska, P. Olko and R. M. Harrison, S. Trinkl. The Influence of Nuclear Models for the Prediction of Secondary Neutrons in Proton Therapy. Under preparation

→ Neutron dose calculations in proton therapy depend on the code and model used

What dose quantity should be measured/simulated?

Case study – Heavy ion radiotherapy during pregnancy (Münter et al, 2010)

- → Active dosimeters
 - → Neutron monitor (MAB NM 500X)
 - → Gamma dose rate meter (TOL/F; Berthold)



H*(10) is not providing you the right organ dose quantities

- Organ dose equivalent (H_T)
 - Secondary charged particles from neutrons
 - Secondary photons

$$H_i = Q_i^n \cdot D_i^n + Q_i^{\gamma} \cdot D_i^{\gamma},$$

Q(E) for neutron up to 20 MeV Siebert and Schumacher, et al., 1995 and NCR for neutrons up to 400 MeV

 $Q^{\gamma} = 1$

What we know...

EURADOS WG9


Out-of-field proton dose

- 1-3 orders of magnitude lower than in photon therapy
- Further away from the target, neutron doses are dominant for the out-of-field doses
- Parameters influencing the dose
 - Use of range shifter
 - Proton energy
 - Field size

Reference

- Patient position
 - Best set-up is perpendicular to the beam


WATER TANK MEASUREMENTS






Reference clinical LINAC Saturn 43, Saclay








Photons Protons

Proton therapy versus photon therapy




EURADOS




Reference

EURADOS


Total fetus dose including imaging dose




Imaging dose optimization



MC simulations





Measurements for imaging






Measurement campaigns in RT clinics





Computational phantoms




MC modeling of neutrons

Phantom measurements of fetus doses in proton and photon radiotherapy



Phantom development



Detectors





Monte Carlo simulations of fetus dose




- Marijke De Saint-Hubert SCK CEN (WG9)
- Hrvoje Brkic MEFOS (WG9-6)
- Katarzyna Tyminska NCBJ (WG6)





instytut kategorii A+, JRC collaboration partner

- Computational estimations of fetus dose during proton brain radiotherapy
 - MCNPx and MCNP6.2
 - Intercomparison of 2 MCNP versions
 - Impact of cross section data and nuclear models on fetus dose
 - Spread out bragg peak to treat brain tumor
 - 3cm collimated proton beam (range 10 modulation 5)
 - Katja (24 weeks) and UF 25 weeks phantom




Circular collimated proton beam of 3 cm diameter

UF 25weeks



Monte Carlo simulations of fetus dose

- Different default cross section libraries between MCNPx and MCNP6.2
 - → Significant impact of data card on fetus dose
- Mix and match option using MX card we unified the cross section libraries and models between MCNPx and MCNP6.2
 - → Very good agreement between codes and participants
- Fetus dose equivalent calculations
 - Photon dose around 15%
 - Fetus dose is dominated by neutrons
 - Fetus dose = $20-40 \mu Sv$
 - 2-fold lower dose for UF25 compared to Katja
 - slightly different stage
 - different orientation



| MCNP | Photon dose equivalent/ target dose | Neutron dose equivalent/ target dose | Total dose equivalent/ target dose | Total dose equivalent for 60 Gy target dose |
|-------------|---|--|--|--|
| Phantom | μSv/Gy | μSv/Gy | μSv/Gy | μSv |
| Katja 24wks | 0.09 | 0.56 | 0.66 | 39 |
| UF 25wks | 0.06 | 0.28 | 0.33 | 20 |

H. Brkic, M. De Saint Hubert, K. Tyminska, L. Stolarczyk - Comparison of the calculated fetus dose during proton therapy of pregnant patient using MCNPX and MCNP6.2. In preparation for Rad Meas 2021.

What's next...








Proton Breast plan on computational phantom

- DICOM-CT of UF 25 weeks phantom
- Danish Centre for Particle Therapy, Aarhus, Denmark
 - Linh My Hoang Thai
 - Maria Fuglsang Jensen
- Left sided breast + 6 lymph nodes
- 3 beams (10, 30, 50 degrees)
 - All using range shifters
- TOPAS wraps and extends the Geant4 Simulation Toolkit
 - DICOM-RT interface
 - Simulate the fetus dose
 - Comparison with MCNP
 - Modeling of neutron dose
 - Impact of simplified beam parameters









Original paper

DICOM-RT Ion interface to utilize MC simulations in routine clinical workflow for proton pencil beam radiotherapy



Jungwook Shin*,b,*, Hanne M. Kooy*,b, Harald Paganetti*,b, Benjamin Clasie*,b

*Department of Resistation Charlogy, Massachusetts General Haspinal, 55 Fruit Street, Baston, MA 02114, USA.
*Harvard Medical School, Boston, MA, USA



Phantom measurements of fetus doses in proton and photon radiotherapy

- Phantom development
 - BfS Sebastian Trinkl



- Currently testing printing approaches and materials
- Measurements photon and proton therapy
 - Interest from WG9 participants
 - Passive (TLD, RPLD, Track edge, BD..) and active detectors (timepix, CMOS, ...)
- Out-of-field dose estimations in proton therapy mixed field
 - Miguel Ángel Caballero-Pacheco (UAB) on 'Methodology on out-of-field doses in proton radiotherapy' – Eurados grant 2021













Total fetus dose including imaging dose



WG 12 - Dosimetry for medical imaging





Sub-group 2 – patient dosimetry

Project on total dose in radiotherapy (WG6/9/12) - Coordinated by Teemu Siiskonen

Imaging doses in radiotherapy

- Assess the situation in Europe (imaging protocols/parameters, estimate patient doses)
- Develop methods for easy estimation of personalised doses from imaging (simulations and empirical methods)
- Collaborate with other organisations to provide good practice guides and recommendations (IAEA, ICRP, EFOMP)





Task 4: Dosimetry in pregnancy related to medical exposure (Dario Faj)

- Review literature and available cases from own practice and experience
- Questionnaire on available algorithms
- Case study/intercomparison plus analysis of uncertainty
- Phantom measurements/MC simulations



Collaboration with hospitals

Clinical experience

Fetus dose from radiotherapy

Different and clinically relevant indications

Different pregnancy stages

Execute clinical plans

- Computational
- Physical phantoms
- Host measurements



- Include imaging + optimization
- Towards individualized dosimetry approach...





Thank you for your attention

Copyright © SCK CEN

PLEASE NOTE!

This presentation contains data, information and formats for dedicated use only and may not be communicated, copied, reproduced, distributed or cited without the explicit written permission of SCK CEN.

If this explicit written permission has been obtained, please reference the author, followed by 'by courtesy of SCK CEN'.

Any infringement to this rule is illegal and entitles to claim damages from the infringer, without prejudice to any other right in case of granting a patent or registration in the field of intellectual property.

SCK CEN

Belgian Nuclear Research Centre

Foundation of Public Utility

Registered Office: Avenue Herrmann-Debrouxlaan 40 – BE-1160 BRUSSELS Operational Office: Boeretang 200 – BE-2400 MOL